

Global Leader in the Biopharma Industry



We are GC Biopharma

GC Biopharma Major Business Portfolio

GC Biopharma has been accumulating expertise in plasma derivatives, vaccines, recombinant proteins, and chemical prescription drugs.

Innovative rare disease medicines

Globally leading plasma-derived medicines

Globally leading diverse vaccines

Trusted expertise in aseptic filling solution

Total solution for mRNA medicines

Hunter syndrome treatment

Albumin, Human immunoglobulin

Varicella and Flu vaccines

CMO (fill & finish)

CDMO (mRNA/LNP)

GC Biopharma At a Glance



It is our MISSION to contribute to the healthy lives of humankind and it is our VISION to be a global leader in the health industry.



7,100+	Employees ¹⁾
\$ 1.7 Bil	'25 Revenue ²⁾
200+	Commercial Products
68	Export Countries

1) This figure represents the total headcount across all GC affiliates on a consolidated basis.

2) Based on GC (Holding Company), consolidated basis.



No.1

- Plasma derivatives
- Vaccines
- Rare disease business in S. Korea



~2025

- 10% IVIG, U.S. FDA Approval
- Varicella Vaccine, WHO P.Q
- Anthrax Vaccine, Approval in South KOR
- MPS IIIA, Orphan Drug Designation




2030

- Global sales + 1.0 Bil USD
- Over +68 Countries

Dedicated Organization

Mission to the healthy lives & Vision to be a global leader



GC Biopharma has solidified its position as **Korea's 1st and best in healthcare.**
We are continuously shaping a healthier future worldwide.

Research & Development Investments



GC Biopharma’s researchers continue to rise to the challenge of saving lives.

2025 R&D Investment Scale

[Consolidated basis]



114.6M[^] USD

2025 R&D expenditure

8.6% Of consolidated revenue invested in R&D

R&D Workforce

[GC Biopharma standalone basis, As of December 2025]



425 R&D professionals

Master’s / Doctorate

297 persons

Bachelor’s

83 persons

Others

45 persons

Advancing global clinical programs across **plasma derivatives, vaccines and rare diseases.**

Global Network

Mission to the healthy lives & Vision to be a global leader



9 Global Operations Across 4 Countries

Medicines Access

Unlimited dedication to the development of safer and more effective treatments

Core Products



Vaccines

- Flu Vaccine
- Varicella Vaccine
- Td Vaccine & 5 Others



Blood Plasma Derived

- Albumin
- Human Immunoglobulin G
- Hyperimmunoglobulin
- Human Coagulation




Rare Disease


- ERT for Hunter syndrome
- Hemophilia A/B type
- Alagille syndrome

Tumor	Treatment for Severe Neutrophil Reduction
Metabolic & Cardiovascular	High blood pressure, Dyslipidemia, Diabetes
OTC Drugs	Vitamins, Painkillers, Patches

Boldness and Passion in our History



Boldness and Passion in our History



Boldness and Passion in our History



2021 World's 1st ERT for Neuronopathic MPSII

The world's 1st ERT for Neuronopathic MPS II
[Hunterase ICV Inj.] has been developed and approved in Japan



2023 IVIg 10% FDA Approval & Successful launching

2023

WHO Pre-Qualification for BARYCELA inj.

WHO Pre-Qualification for BARYCELA inj.
WHO Pre-Qualification for Hwasun plant
WHO Pre-Qualification
for Fill and Finish plant of Ochang Plant



2025

World's 1st Recombinant Anthrax Vaccine

[BARYTHRAX] Approved and Launched in South Korea



We always welcome the challenge of developing new medicine.

R&D Pipeline (as of June 2026)



	Preclinical >>>	Phase I >>>	Phase II >>>	Phase III >>>	Registration / Approved
Plasma Derivatives	GC5125 vWF deficiency GC5136 PID (SC)			GC5107 US PID (Pediatric)	GC5107 US PID
Vaccines	GC4002 mRNA Flu vaccine GC1140 EBV vaccine		GC4006A mRNA COVID vaccine GC3111 Tdap vaccine GC3114B TIV-HD(Ph2/3)	MG1111 Thailand Varicella vaccine (2 dose)	MG1111 Varicella vaccine GC1106 H5N1 pandemic vaccine GC1109 Anthrax vaccine
Innovative medicines	GC1126 TTP GC2126 Gangliosidosis GC1148 ADC for solid tumors	MG113 Hemophilia A/B GC1130 US MPSIIIA (Ph1)	GC1134 US Fabry disease (Ph1/2)	GC1138 Glanzmann's disease	GC2127 Alagille syndrome GC1101 China Hemophilia A GC1111 Hunter syndrome GC1134 US Hunter syndrome (Severe type) (NDA)

Site 1_Ochang

Asia's Largest Plasma Processing Facility, Certified Globally from the US FDA to WHO



Established	2010 / 2019
Location	Ochang, South Korea
Area (F&F)	131,959 m ²
Products	Plasma & Recombinant Proteins, mRNA, AAV, C>
Key Services	Aseptic Fill & Finish, Logistics
Containers	Vials

- ☑ WHO PQ / Ministry of Food and Drug Safety authorization Completed / FDA
- ☑ Formulation - filling - Lyo - packaging - release
- ☑ High speed Isolator line (Vial) & BSL-2
- ☑ Automatic visual inspection
- ☑ Automatic labeling and packaging system
- ☑ Automated warehouse-barcode system



Site 2_Hwasun

Korea's largest vaccine production site




Established	2010
Location	Hwasun, South Korea
Area (F&F)	98,963 m ²
Products	Vaccines
Key Services	Aseptic Fill & Finish
Containers	Vial & Pre-filled syringe

- ✓ WHO PQ / Ministry of Food and Drug Safety authorization Completed / FDA
- ✓ Formulation - filling - Lyo - packaging - release
- ✓ Liquid Vials Filling (BSL 2 Available)
- ✓ Automatic visual inspection
- ✓ Automatic labeling and packaging system
- ✓ Packaging Aggregation system / serialization
- ✓ mRNA Facilities (Drug Substance) for 2025




CMO (Fill & Finish)

No.1 Aseptic Fill & Finish CMO Capacity in Korea



CMO Professional Personnel
(DP+QM+RA)



Filling Solutions

From small to large scale production
(5L - 1,000L)

Packaging Solutions

Diverse packaging format

Quality Management System

Regulatory track records
(68 countries)

CMO (Fill & Finish)

No.1 Aseptic Fill & Finish CMO Capacity in Korea

All our Quality System Satisfies cGMP

Change Control
System



Deviation System



Out of Specification
System



Supplier
Management System



Product
Complaint System



Training System



Warehousing
System



Recall System



IT System



Equipment Life Cycle
Management System



Laboratory System



Document Management
System



